StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Reaktion

Triethylamine → (R)-1-(4-methyl-2-oxo-2,3-dihydro-benzoxazol-6-ylmethyl)-2-oxo-2-(4-oxo-piperidin-1-yl)-ethyl 4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

HRID 1864620
Drucken

Reaktionsgleichung

Reaktionsgleichung von HRID 1864620
[NH:1]1[CH2:6][CH2:5][C:4](=[O:7])[CH2:3][CH2:2]1.[O:8]=[C:9]1[N:15]([CH:16]2[CH2:21][CH2:20][N:19]([C:22]([O:24][C@@H:25]([C:38](O)=[O:39])[CH2:26][C:27]3[CH:36]=[C:35]([CH3:37])[C:30]4[NH:31][C:32](=[O:34])[O:33][C:29]=4[CH:28]=3)=[O:23])[CH2:18][CH2:17]2)[CH2:14][CH2:13][C:12]2[CH:41]=[CH:42][CH:43]=[CH:44][C:11]=2[NH:10]1.CN(C(ON1N=NC2C=CC=CC1=2)=[N+](C)C)C.[B-](F)(F)(F)F.C(N(CC)CC)C>CN(C=O)C>[O:8]=[C:9]1[N:15]([CH:16]2[CH2:17][CH2:18][N:19]([C:22]([O:24][C@H:25]([CH2:26][C:27]3[CH:36]=[C:35]([CH3:37])[C:30]4[NH:31][C:32](=[O:34])[O:33][C:29]=4[CH:28]=3)[C:38](=[O:39])[N:1]3[CH2:6][CH2:5][C:4](=[O:7])[CH2:3][CH2:2]3)=[O:23])[CH2:20][CH2:21]2)[CH2:14][CH2:13][C:12]2[CH:41]=[CH:42][CH:43]=[CH:44][C:11]=2[NH:10]1
KomponentenVersuchsvorschriftAufarbeitungQuellen und NachweiseNotizen zur Reaktion

Komponenten

6

Edukt 4

HCID 8471TriethylamineHCID 337214-PiperidoneHCID 2733207O-(Benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborateHCID 68608307(R)-1-carboxy-2-(4-methyl-2-oxo-2,3-dihydrobenzoxazol-6-yl)-ethyl 4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

Produkt 1

HCID 69058954
(R)-1-(4-methyl-2-oxo-2,3-dihydro-benzoxazol-6-ylmethyl)-2-oxo-2-(4-oxo-piperidin-1-yl)-ethyl 4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

Reagenzien, Katalysatoren, Lösungsmittel 1

HCID 6228DimethylformamideLösungsmittel

Versuchsvorschrift

200 mg (1.30 mmol) piperidin-4-one (used as the hydrate of the hydrochloride salt) were added to a solution of 500 mg (0.98 mmol) (R)-1-carboxy-2-(4-methyl-2-oxo-2,3-dihydrobenz-oxazol-6-yl)-ethyl 4-(2-oxo-1,2,4,5,-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate, 350 mg (1.09 mmol) TBTU, 300 μL (2.15 mmol) triethylamine in 10 mL DMF and the reaction mixture was stirred for 4 h at RT. The reaction solution was evaporated down i. vac., the residue was taken up in DCM, the organic phase was washed with saturated NaHCO3 solution and dried on Na2SO4. After the desiccant and solvent had been eliminated the residue was purified by chromatography (silica gel, gradient DCM/MeOH 20:1 to DCM/MeOH 10:1). The fractions containing the product were concentrated by evaporation, the residue was stirred with DIPE, suction filtered and dried.

Aufarbeitung

  1. customThe reaction solution was evaporated down i
  2. washthe organic phase was washed with saturated NaHCO3 solution
  3. customdried on Na2SO4
  4. customwas purified by chromatography (silica gel, gradient DCM/MeOH 20:1 to DCM/MeOH 10:1)
  5. additionThe fractions containing the product
  6. concentrationwere concentrated by evaporation
  7. stirringthe residue was stirred with DIPE, suction
  8. filtrationfiltered
  9. customdried

Quellen und Nachweise

ORD-Eintrag
ord-b68cb5cac5454edd87d355d890085329
Quelldatensatz
uspto-grants-2009_12
DOI
10.6084/m9.figshare.5104873.v1
Patentnummer
US07625886B2

Notizen zur Reaktion

Auf dieser SeiteKomponentenVersuchsvorschriftAufarbeitungQuellen und NachweiseNotizen zur Reaktion